Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Cardiorenal benefits of sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus
EF 2021-22
Résumé
Diabetes mellitus is one of the fastest growing public health crises worldwide and accounts for 6% of global prevalence. Chronic high blood glucose, a hallmark of diabetes, stems from impaired insulin release or action, defined as type 1 diabetes (T1D) or type 2 diabetes (T2D) respectively, and can implicate a myriad of complications. Namely, diabetes is one of the leading causes of chronic kidney disease (CKD) and is a prime risk factor for cardiovascular disease (CVD). Until recently, the most effective treatment plan for diabetes-associated CVD and CKD was to monitor blood pressure and glucose. This shifted when sodium-glucose cotransporter 2 (SGLT2) inhibitors revolutionized clinical practice for people with T2D. The anti-diabetic agents act on kidney tubules to block glucose reabsorption, thereby decreasing blood sugar. Intriguingly, SGLT2 inhibitors were also reported to display protective effects against CVD and CKD progression. Since this discovery was serendipitous, the mechanisms that underpin these observed clinical benefits remain unclear. Addedly, as SGLT2 inhibitors have mainly been studied as a T2D therapeutic, the potential benefits in T1D are incompletely understood. In my study, I will advance our current state of knowledge by investigating how SGLT2 inhibitors elicit protection against CKD and CVD risk in T1D patients. To investigate this, I will (1) contrast the expression of molecular markers between T1D patients at high and low risk of CVD or CKD and (2) examine whether intervention modifies the T1D-specific marker profile. By exploring mechanisms of SGLT2 inhibitors, health research can expand treatment options for additional patient groups, including those with T1D, CKD, and CVD, in hopes of reducing diabetes-related complications and mortality.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
467193
Name
Kugathasan Luxcia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Cardiorenal benefits of sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Cardiorenal Protection; Cardiovascular Disease; Chronic Kidney Disease; Dapa-Sweet Trial; Diabetes Longevity Study; Diabetes Mellitus; Diabetic Kidney Disease; Sglt2 Inhibitors; Type 1 Diabetes
Abstract
Diabetes mellitus is one of the fastest growing public health crises worldwide and accounts for 6% of global prevalence. Chronic high blood glucose, a hallmark of diabetes, stems from impaired insulin release or action, defined as type 1 diabetes (T1D) or type 2 diabetes (T2D) respectively, and can implicate a myriad of complications. Namely, diabetes is one of the leading causes of chronic kidney disease (CKD) and is a prime risk factor for cardiovascular disease (CVD). Until recently, the most effective treatment plan for diabetes-associated CVD and CKD was to monitor blood pressure and glucose. This shifted when sodium-glucose cotransporter 2 (SGLT2) inhibitors revolutionized clinical practice for people with T2D. The anti-diabetic agents act on kidney tubules to block glucose reabsorption, thereby decreasing blood sugar. Intriguingly, SGLT2 inhibitors were also reported to display protective effects against CVD and CKD progression. Since this discovery was serendipitous, the mechanisms that underpin these observed clinical benefits remain unclear. Addedly, as SGLT2 inhibitors have mainly been studied as a T2D therapeutic, the potential benefits in T1D are incompletely understood. In my study, I will advance our current state of knowledge by investigating how SGLT2 inhibitors elicit protection against CKD and CVD risk in T1D patients. To investigate this, I will (1) contrast the expression of molecular markers between T1D patients at high and low risk of CVD or CKD and (2) examine whether intervention modifies the T1D-specific marker profile. By exploring mechanisms of SGLT2 inhibitors, health research can expand treatment options for additional patient groups, including those with T1D, CKD, and CVD, in hopes of reducing diabetes-related complications and mortality.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kugathasan, Luxcia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~